Obtenga las últimas noticias sobre las acciones de Capricor Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de CAPR

Últimas noticias sobre

CAPRICOR THERAPEUTICS INC

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Acciones que se mueven

ARHS

BASE

CAPR

CDNA

CTOR

DGLY

HLMN

ICCT

NTHI

TILE

Xos sorprende al mercado con sólidos resultados en 2024 y hace subir sus acciones antes de la apertura. Descubre más movimientos aquí.

Acciones de Xos (XOS) suben alrededor de un 9%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

Capri Holdings Ltd

CAPRAL LTD by Capral Ltd.

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

Press Releases

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

News

Legal

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR

CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Health Care

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Altimmune

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

Editas Medicine

enGene Holdings

ETHZilla

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Kamada

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

PepGen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Rocket Pharmaceuticals, Inc. - Common Stock

Comments

Capricor Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL